38,676 Shares in Edgewise Therapeutics, Inc. $EWTX Purchased by Knights of Columbus Asset Advisors LLC

Knights of Columbus Asset Advisors LLC bought a new position in shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) during the fourth quarter, Holdings Channel reports. The fund bought 38,676 shares of the company’s stock, valued at approximately $960,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Optimize Financial Inc grew its stake in shares of Edgewise Therapeutics by 1.5% in the 4th quarter. Optimize Financial Inc now owns 27,679 shares of the company’s stock valued at $687,000 after buying an additional 396 shares during the period. California State Teachers Retirement System lifted its holdings in Edgewise Therapeutics by 2.4% in the second quarter. California State Teachers Retirement System now owns 36,878 shares of the company’s stock valued at $483,000 after acquiring an additional 850 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Edgewise Therapeutics by 26.3% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,145 shares of the company’s stock valued at $128,000 after acquiring an additional 1,072 shares during the last quarter. Creative Planning grew its position in Edgewise Therapeutics by 6.7% in the third quarter. Creative Planning now owns 18,036 shares of the company’s stock worth $293,000 after acquiring an additional 1,126 shares during the period. Finally, Tower Research Capital LLC TRC increased its stake in Edgewise Therapeutics by 14.9% during the second quarter. Tower Research Capital LLC TRC now owns 9,148 shares of the company’s stock worth $120,000 after acquiring an additional 1,188 shares during the last quarter.

Insiders Place Their Bets

In other Edgewise Therapeutics news, CMO Joanne M. Donovan sold 50,000 shares of the stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $38.57, for a total transaction of $1,928,500.00. Following the sale, the chief marketing officer directly owned 4,367 shares in the company, valued at $168,435.19. This represents a 91.97% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last quarter, insiders have sold 83,892 shares of company stock worth $3,018,216. 23.20% of the stock is owned by corporate insiders.

Edgewise Therapeutics Stock Down 0.7%

Shares of NASDAQ EWTX opened at $33.30 on Friday. The business’s 50 day moving average is $32.65 and its two-hundred day moving average is $28.58. Edgewise Therapeutics, Inc. has a 52-week low of $12.15 and a 52-week high of $39.96. The firm has a market cap of $3.58 billion, a price-to-earnings ratio of -20.06 and a beta of 0.25.

Edgewise Therapeutics (NASDAQ:EWTX) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.04. Analysts anticipate that Edgewise Therapeutics, Inc. will post -2.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Wedbush restated an “outperform” rating and issued a $32.00 target price on shares of Edgewise Therapeutics in a research report on Tuesday, March 17th. Stifel Nicolaus set a $25.00 price target on Edgewise Therapeutics in a report on Thursday, February 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Edgewise Therapeutics in a research report on Monday, April 20th. JPMorgan Chase & Co. upped their target price on shares of Edgewise Therapeutics from $34.00 to $45.00 and gave the company an “overweight” rating in a research report on Tuesday, March 17th. Finally, Truist Financial set a $52.00 target price on shares of Edgewise Therapeutics in a research note on Wednesday, May 6th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Edgewise Therapeutics has an average rating of “Moderate Buy” and an average target price of $39.67.

About Edgewise Therapeutics

Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.

At the core of Edgewise’s pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.